title: Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells.
abstract: Sulfatide (3'sulfogalactosylceramide) is the natural sulfated derivative of galactosylceramide (GalCer), a glycosphingolipid receptor allowing HIV-1 infection of CD4-negative cells from neural and intestinal tissues. The incorporation of exogenous sulfatide into the plasma membrane of HT-29 (a CD4-/GalCer+/CXCR4+ human intestinal cell line) or RD (CD4-/GalCer-/ CXCR4+ human rhabdomyosarcoma) resulted in a dose-dependent inhibition of HIV-1 infection. Experiments with luciferase reporter viruses pseudotyped with HIV-1 or amphotropic murine leukemia virus envelopes demonstrated that sulfatide acts at the level of viral entry. Paradoxically, the transfer of sulfatide in the plasma membrane of various CD4- cells resulted in increased binding of HIV-1. Surface pressure measurements were conducted to study the interaction of gp120 with glycosphingolipid monolayers. The data showed that gp120 could penetrate into a monomolecular film of GalCer, confirming the role of this glycosphingolipid as a functional receptor for HIV-1. In contrast, the insertion of gp120 into a monolayer of sulfatide was very limited. Moreover, the incorporation of sulfatide in a monomolecular film of GalCer specifically inhibited the penetration of gp120. In conclusion, these data show that sulfatide mediates gp120 binding but, in marked contrast with GalCer, is not able to initiate the fusion event.
authors.affiliation: Laboratoire de Biochimie et Biologie de la Nutrition, CNRS ESA 6033, Faculté des Sciences St. Jérôme, Marseille, France. JACQUES.FANTINI@LBBN.u-3mrs.fr
authors.forename: J
authors.initials: J
authors.lastname: Fantini
authors.forename: D
authors.initials: D
authors.lastname: Hammache
authors.forename: O
authors.initials: O
authors.lastname: Delézay
authors.forename: G
authors.initials: G
authors.lastname: Piéroni
authors.forename: C
authors.initials: C
authors.lastname: Tamalet
authors.forename: N
authors.initials: N
authors.lastname: Yahi
mesh_terms: D015704:CD4 Antigens; D018938:Caco-2 Cells; D005699:Galactosylceramides / Q000378:metabolism; D017353:Gene Deletion; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology*; D019073:HT29 Cells; D006801:Humans; D010446:Peptide Fragments / Q000378:metabolism; D019718:Receptors, CXCR4; D013433:Sulfoglycosphingolipids / Q000378:metabolism / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D015704:CD4 Antigens; D005699:Galactosylceramides; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D019718:Receptors, CXCR4; D013433:Sulfoglycosphingolipids